更新于：2024-11-15
Betahistine Mesilate
甲磺酸倍他司汀
更新于：2024-11-15
概要
基本信息
药物类型 小分子化药 |
别名 Betahistine mesilate (JP17)、Meniace、Merislon + [1] |
作用机制 组胺受体家族拮抗剂 |
非在研适应症- |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C10H20N2O6S2 |
InChIKeyZBJJDYGJCNTNTH-UHFFFAOYSA-N |
CAS号54856-23-4 |
关联
11
项与 甲磺酸倍他司汀 相关的临床试验甲磺酸倍他司汀片在健康受试者空腹和餐后状态下的随机、开放、单剂量、两制剂、两周期、两序列、交叉生物等效性试验
甲磺酸倍他司汀片在健康受试者中空腹/餐后单次口服给药、随机、开放、两序列、两周期、交叉生物等效性试验
在健康成年受试者中进行的单中心、随机、开放、两周期、两序列、交叉、单次给药试验设计，评价空腹/餐后状态下的生物等效性研究。
100 项与 甲磺酸倍他司汀 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸倍他司汀 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸倍他司汀 相关的专利（医药）
登录后查看更多信息
22
项与 甲磺酸倍他司汀 相关的文献（医药）2024-10-01JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
Betahistine mesylate reduces the damage of blue light exposure in Drosophila model
Article
作者: He, Jianan ; Shen, Jie ; Zhao, Zhiwei ; Li, Xiangyu
Previous studies have demonstrated the efficacy of betahistine mesylate in treating vertigo and angioneurotic headache, enhancing microcirculation, and facilitating histamine release. However, limited research has been conducted on the drug's potential in mitigating blue light-induced damage. Thus, this study utilized Drosophila as the model organism and employed the Siler model to investigate the impact of various concentrations of betahistine mesylate on the lifespan, under 3000 lx blue light irradiation. At the same time we measure food intake, spontaneous activity, and sleep duration of Drosophila. The findings of this study indicate that a high concentration of betahistine mesylate can decrease the initial mortality (b0) in male flies, mitigating the damage of blue light to Drosophila. Consequently, this delays the aging process in male Drosophila and extends their average lifespan. After betahistine mesylate ingestion, locomotor activity upon blue light exposure decreased significantly in male Drosophila. In conclusion, this study offers initial evidence supporting the investigation of the regulatory mechanisms of betahistine mesylate on lifespan and its potential anti-blue light effects.
2024-10-01Contemporary Clinical Trials Communications
Safety and efficacy of traditional Chinese manual therapy for cervicogenic dizziness: study protocol for a randomized, controlled, multicenter trial
Article
作者: Liu, Kaoqiang ; Chai, Yongli ; Kong, Lingjun ; Zhao, Ye ; Yuan, Weian ; Zhan, Yunfan ; Zhang, Yujie ; Ning, Jiawei
Background:
Cervicogenic dizziness is a clinical syndrome characterized by neck pain and dizziness, which has a rising incidence in recent years. In China, manual therapy has been widely used in the treatment of cervicogenic dizziness, but there is no high-quality medical evidence to support its effectiveness and safety. The purpose of this study was to assess the safety and efficacy of Shi's manual therapy (SMT) on the treatment of cervicogenic dizziness.
Methods:
A multicenter randomized controlled trial (RCT) will perform on 106 patients (18≤ages≤65) who meet the diagnostic criteria of cervicogenic dizziness. Patients will be randomly allocated to the intervention group and the control group at a ratio of 1:1. Participants in the control group will be treated with Merislon (Betahistine Mesilate Tablets). Participants in the intervention group will be treated with SMT. The primary outcome is the response rate at week 2, which is defined as the proportion of patients who reduce their disability level measured by the Dizziness Handicap Inventory (DHI) score relative to baseline. Key secondary outcomes include DHI scores at weeks 1, 2, and 6 and changes from baseline, time to disappearance of dizziness symptoms, and recurrence rate of dizziness symptoms. Safety will be assessed by adverse events, physical examination and vital signs.
Discussion:
This trial aims to provide high-quality evidence-based medical data to demonstrate that SMT can reduce dizziness in patients with cervicogenic dizziness effectively and safely.
Trial registration:
Clinical Trial Registration Center NCT05604937. Registered on Nov 3, 2022.
Protocol version:
1.0, November 20, 2022.
2023-11-01Brain stimulation
Meniere Disease treated with transcutaneous auricular vagus nerve stimulation combined with betahistine Mesylate: A randomized controlled trial
Article
作者: Wu, Yunqing ; Wang, Yu ; Wu, Dong ; Cao, Kai ; Sun, Jingyi ; Liu, Bo ; Liu, Gang ; Rong, Peijing ; Duan, Jinping ; Yang, Jun ; Zhang, Yi
BACKGROUND:
Meniere Disease is a clinical condition defined by hearing loss, tinnitus, and aural fullness symptoms, there are currently no any medications approved for its treatment.
OBJECTIVE:
To determine whether taVNS as an adjunctive therapy could relieve symptoms and improve the quality of life in patients with Meniere disease.
METHODS:
In this Single-center, single blind, randomized trial, participants were assigned to transcutaneous auricular vagus nerve stimulation (taVNS) group and sham taVNS group. The primary outcome measures comprised Tinnitus Handicap Inventory, Dizziness Handicap Inventory, Pure Tone Auditory, Visual analogue scale of aural fullness. Secondary outcome measures comprised the 36-Item Short Form Health Survey, video head impulse test, and the caloric test.
RESULTS:
After 12 weeks, the THI (-11.00, 95%CI, -14.87 to -7.13; P < 0.001), DHI (-47.26, 95%CI, -50.23 to -44.29; P < 0.001), VAS of aural fullness (-2.22, 95%CI, -2.95 to -1.49; P<0.01), and Pure Tone Thresholds (-7.07, 95%CI, -9.07 to -5.06; P<0.001) were significantly differed between the two groups. In addition, SF36(14.72, 95%CI, 11.06 to 18.39; P < 0.001), vHIT (RD, 0.26, 95 % CI, -0.44 to -0.08, RR, 0.43, 95 % CI, 0.22 to 0.83, P < 0.01), and the caloric test (RD, -0.24, 95 % CI, -0.43 to -0.04, RR, 0.66, 95 % CI, 0.44 to 0.95, P = 0.02) have significant difference between two group, respectively.
CONCLUSIONS:
These findings suggest that taVNS combined with Betahistine Mesylate relieve symptoms and improve the quality of life for patients with Meniere Disease. taVNS can be considered an adjunctive therapy in treatment of Meniere Disease.
TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT05328895.
100 项与 甲磺酸倍他司汀 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 梅尼埃病 | 日本 | 1969-01-01 | |
| 眩晕 | 日本 | 1969-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用